October 2022 updates to the website
19 October 2022
The website has now been updated following October's LSCMMG
The following guidelines have been added/updated:
Use of medicines outside of their UK Marketing Authorisation in pain management - updated
Generic biosimilar medicines position statement - update to follow
Asthma treatment guideline for adults aged 17 and over - updated
Atrial Fibrillation pathway - updated
The following Items have been updated and added to the website following the latest Pharmacy and Medicines Policy Task and Finish Group Meeting:
Paliperidone palmitate prolonged release suspension for injection (six monthly) - Treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products
Mexiletine - Treatment of documented ventricular arrhythmias which, in the judgement of the physician, are considered as life-threatening.
Testosterone gel - As supplementation for menopausal women with low sexual desire if HRT alone is not effective
Vedolizumab SC - Crohn's disease & Ulcerative colitis
Infliximab SC - Crohn's disease & Ulcerative colitis
Botulinum Toxin Type A - For treatment of primary idiopathic hyperhidrosis and secondary hyperhidrosis
Liothyronine - Add-on treatment for refractory hypothyroidism despite adequate replacement with levothyroxine – new patients
Liothyronine - Add-on treatment for refractory hypothyroidism – existing patients.
Liothyronine - Liothyronine monotherapy for the management of chronic hypothyroidism – primary and secondary care
Romosozumab - severe osteoporosis (NICE TA791)
Filgotinib - for treating moderately to severely active ulcerative colitis (NICE TA792)
Faricimab - for treating diabetic macular oedema (NICE TA799)
Faricimab - for treating wet age-related macular degeneration (NICE TA800)
Risankizumab - treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA803)
Roxadustat - treating symptomatic anaemia in chronic kidney disease (NICE TA807)
Abrocitinib, tralokinumab or upadacitinib - treating moderate to severe atopic dermatitis (NICE TA814)
Guselkumab - treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA815)
Brolucizumab - treating diabetic macular oedema (NICE TA820)
The following Items will be updated and added to the website following the next Pharmacy and Medicines Policy Task and Finish Group Meeting:
Icosapent ethyl with statin therapy - for reducing the risk of cardiovascular events in people with raised triglycerides (NICE TA805)
Dexamethasone intravitreal implant - treating diabetic macular oedema (NICE TA824) replaces NICE TA349
Trimbow MDI - Asthma
Hydrocortisone sodium phosphate eye drops (Softacort) - Treatment of mild non-infectious allergic or inflammatory conjunctival diseases